国金证券股份有限公司 一、 募集资金基本情况 经中国证券监督管理委员会于 2021 年 8 月 3 日发布的《关于同意上海谊众 药业股份有限公司首次公开发行股票注册的批复》（证监许可[2021]2595 号）同 意，公司向社会公众公开发行人民币普通股（A 股）股票 2,645.00 万股，每股面 值 1 元，发行价格为每股人民币 38.10 元，募集资金总额为人民币 100,774.50 万 元，扣除发行费用 7,171.45 万元，募集资金净额为 93,603.05 万元。 截至 2021 年 9 月 3 日，公司本次募集资金净额 93,603.05 万元已全部到位， 并由容诚会计师事务所（特殊普通合伙）对公司募集资金的到位情况进行了审验， 并出具了容诚验字[2021]201Z0041 号《验资报告》，公司依照规定对上述募集资 金进行专户存储管理，并与保荐机构、募集资金专户监管银行签订了募集资金专 户存储监管协议。 二、募集资金使用情况 按照上海谊众《首次公开发行股票并在科创板上市招股说明书》披露的募集 资金投资项目及募集资金使用计划，以及公司根据实际募集资金的情况对募投项 目使用募集资金金额进行的调整，公 ...

格隆汇8月7日丨上海谊众(688091.SH)公布半年度报告，2025年上半年，核心产品紫杉醇胶束销量较去 年同期增长约487%，实现营业收入16,030.74万元，较去年同期增长31.48%；归属于上市公司股东的净 利润3,800.38万元，较去年同期增长10.13%；归属于上市公司股东扣除非经常性损益的净利润3,705.56 万元，较去年同期增长11.74%。 ...

人民财讯8月7日电，上海谊众(688091)8月7日晚间披露2025年半年度报告，公司上半年实现营业收入1.6 亿元，同比增长31.48%；归母净利润3800.38万元，同比增长10.13%；基本每股收益0.18元。 ...

Group 1 - The core viewpoint of the article highlights that Shanghai Yizhong reported a revenue of 160 million yuan in the first half of 2025, representing a year-on-year growth of 31.48% [1] - The net profit for the same period was 38.0038 million yuan, showing a year-on-year increase of 10.13% [1] - The significant revenue growth is primarily attributed to the inclusion of the core product, paclitaxel micelles, in the national medical insurance catalog, which led to a remarkable sales increase of 487% compared to the same period last year [1]

Wind统计显示，8月1日，科创板两融余额合计1736.5亿元，较上一交易日增加3.99亿元。其中，融资余 额合计1730.33亿元，较上一交易日增加4.16亿元；融券余额合计6.17亿元，较上一交易日减少0.17亿 元。 从个股来看，8月1日有264只科创板个股获融资净买入，净买入金额在5000万元以上的有10股。其中， 瑞可达获融资净买入额居首，净买入2.43亿元；融资净买入金额居前的还有东芯股份、九号公司、上海 谊众、海光信息、中微公司、索辰科技等股，净买入额分别为8427.48万元、8298.09万元、7864.68万 元、7471.11万元、6672.38万元、6101.01万元。 （文章来源：证券时报网） ...

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 34.062 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 4.184 billion yuan [1] - A total of 242 stocks saw net inflows, while 345 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 341 stocks rose, with two stocks, Ruikeda and Shenlian Biological, hitting the daily limit, while 241 stocks declined [1] - The stocks with the highest net inflows included Gaoce Co., Ltd. with 107.17 million yuan, followed by Jinpan Technology and Shanghai Yizhong with 89.50 million yuan and 89.26 million yuan respectively [2] Continuous Fund Flow - There are 39 stocks that have seen continuous net inflows for more than three trading days, with Kexin Co., Ltd. leading at eight consecutive days of inflow [2] - Conversely, 194 stocks have experienced continuous net outflows, with ST Yifei leading at 15 consecutive days of outflow [2] Key Stocks with Fund Inflows - The top stocks by net inflow include: - Gaoce Co., Ltd. (107.17 million yuan, 16.58% inflow rate, 1.91% increase) [2] - Jinpan Technology (89.50 million yuan, 7.08% inflow rate, 6.89% increase) [2] - Shanghai Yizhong (89.26 million yuan, 9.54% inflow rate, 7.79% increase) [2] Key Stocks with Fund Outflows - The stocks with the highest net outflows include: - Dongxin Co., Ltd. (816 million yuan, 11.37% decrease) [1] - Hanwujing and Lankai Technology with net outflows of 411 million yuan and 391 million yuan respectively [1]

Group 1 - The core viewpoint highlights the active trading and significant growth of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, with a turnover rate of 21.72% and a transaction volume of 47.63 million yuan on July 31 [2] - Over the past week, the Sci-Tech Pharmaceutical ETF has seen an average daily transaction volume of 53.21 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 16.78 million yuan in the past week, also leading among comparable funds, with a share increase of 12.50 million shares [2] Group 2 - The fund has attracted a total of 14.72 million yuan in inflows over the last five trading days [2] - As of July 31, the net value of the Sci-Tech Pharmaceutical ETF has risen by 48.77% over the past year, ranking 350 out of 2943 in the index stock fund category, placing it in the top 11.89% [2] - The fund's highest monthly return since inception was 23.29%, with the longest consecutive monthly gain being six months and a maximum increase of 41.76% [2] Group 3 - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - The stock performance of the top ten companies shows mixed results, with some stocks experiencing slight declines while others have positive growth [4] Group 4 - The National Healthcare Security Administration has established a "new drug first launch price mechanism" to encourage drug research and innovation, marking a significant policy development [4] - The pharmaceutical and biotech sectors are expected to benefit from a high level of innovation and a potential revaluation of value stocks, with recommendations for companies in the Pharma and Biopharma/Biotech sectors [5] - The medical device industry is also anticipated to benefit from policy optimizations, with recent statements from relevant authorities supporting innovation and addressing issues of internal competition [5]

证券之星消息，7月30日化学制药板块较上一交易日下跌0.01%，昂利康领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688189 | 南新制药 | 14.28 | 20.00% | 50.53万 | | 6.93亿 | | 688091 | 上海谊众 | 75.40 | 14.68% | 16.63万 | | 12.83亿 | | 000953 | 河化股份 | 8.02 | 10.01% | 49.98万 | | 3.89亿 | | 002675 | 东诚药业 | 17.60 | 10.00% | 21.04万 | | 3.66亿 | | 603367 | 辰欣药业 | 28.52 | 9.99% | 27.34万 | | 7.77亿 | | 605507 | 围邦医药 | 23.68 | 9.99% | 16.00万 | | 3.75亿 | ...

截至2025年7月30日 11:14，上证科创板生物医药指数上涨0.67%，成分股上海谊众上涨19.38%，首药控股上涨12.60%，复旦张江上涨6.23%，益诺思上涨 3.68%，百奥泰上涨3.62%。科创医药ETF嘉实(588700)上涨0.84%， 冲击3连涨。 流动性方面，科创医药ETF嘉实盘中换手15.83%，成交3528.42万元，市场交投活跃。拉长时间看，截至7月29日，科创医药ETF嘉实近1周日均成交4604.82 万元，排名可比基金第一。 截至7月29日，科创医药ETF嘉实近1年净值上涨59.34%，指数股票型基金排名304/2939，居于前10.34%。从收益能力看，截至2025年7月29日，科创医药ETF 嘉实自成立以来，最高单月回报为23.29%，最长连涨月数为5个月，最长连涨涨幅为23.50%，上涨月份平均收益率为7.43%。 数据显示，截至2025年6月30日，上证科创板生物医药指数前十大权重股分别为联影医疗、百济神州、惠泰医疗、百利天恒、艾力斯、泽璟制药、君实生 物、博瑞医药、华大智造、益方生物，前十大权重股合计占比50.3%。 | 股票代码 | 股票简称 | 涨跌幅 | 权重 ...

融资融券数据显示，该股最新（7月29日）两融余额为4.15亿元，其中，融资余额为4.13亿元，较上一个 交易日增加680.66万元，增幅为1.67%；融券余额为164.21万元，较上一个交易日增加16.96万元，增幅 为11.52%。近10日两融余额合计减少1.14亿元，降幅为21.54%，其间融资余额下降21.62%，融券余额增 长5.10%。（数据宝） （文章来源：证券时报网） 科创板个股中，截至发稿上涨的共有158只，涨幅在5%以上的共有7只，涨幅较高的有上海谊众、南新 制药、*ST天微等，分别上涨20.00%、12.94%、6.86%，下跌的有424只，跌幅较大的有仕佳光子、悦康 药业、金橙子，分别下跌10.42%、6.09%、5.60%。 资金面上，上海谊众上一交易日主力资金净流入3001.34万元，近5日净流出3819.05万元。 7月30日盘中科创板股上海谊众涨停，截至09:35，股价报78.90元，成交4.01亿元，换手率2.56%，振幅 11.50%。 ...